JP2022536370A5 - - Google Patents

Info

Publication number
JP2022536370A5
JP2022536370A5 JP2021573797A JP2021573797A JP2022536370A5 JP 2022536370 A5 JP2022536370 A5 JP 2022536370A5 JP 2021573797 A JP2021573797 A JP 2021573797A JP 2021573797 A JP2021573797 A JP 2021573797A JP 2022536370 A5 JP2022536370 A5 JP 2022536370A5
Authority
JP
Japan
Application number
JP2021573797A
Other languages
Japanese (ja)
Other versions
JPWO2020252471A5 (https=
JP2022536370A (ja
JP7680967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037781 external-priority patent/WO2020252471A1/en
Publication of JP2022536370A publication Critical patent/JP2022536370A/ja
Publication of JP2022536370A5 publication Critical patent/JP2022536370A5/ja
Publication of JPWO2020252471A5 publication Critical patent/JPWO2020252471A5/ja
Priority to JP2025078346A priority Critical patent/JP2025121996A/ja
Application granted granted Critical
Publication of JP7680967B2 publication Critical patent/JP7680967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573797A 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法 Active JP7680967B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078346A JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861643P 2019-06-14 2019-06-14
US62/861,643 2019-06-14
PCT/US2020/037781 WO2020252471A1 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078346A Division JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022536370A JP2022536370A (ja) 2022-08-15
JP2022536370A5 true JP2022536370A5 (https=) 2023-06-21
JPWO2020252471A5 JPWO2020252471A5 (https=) 2023-06-21
JP7680967B2 JP7680967B2 (ja) 2025-05-21

Family

ID=73781315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573797A Active JP7680967B2 (ja) 2019-06-14 2020-06-15 Pd-1に対する抗体およびその使用方法
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078346A Pending JP2025121996A (ja) 2019-06-14 2025-05-09 Pd-1に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220275088A1 (https=)
EP (1) EP3982997A4 (https=)
JP (2) JP7680967B2 (https=)
AU (1) AU2020290971A1 (https=)
CA (1) CA3141628A1 (https=)
WO (1) WO2020252471A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US20100233154A1 (en) * 2008-10-08 2010-09-16 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
JP2014533659A (ja) * 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
HK1254803A1 (zh) * 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
CN114605548A (zh) * 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
EP3497124A1 (en) * 2016-08-12 2019-06-19 ARSANIS Biosciences GmbH Klebsiella pneumoniae o3 specific antibodies
US20230192839A1 (en) * 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
US20200354460A1 (en) * 2017-09-29 2020-11-12 Wuxi Biologics Ireland Limited. Bispecific antibodies against EGFR and PD-1
WO2020113224A2 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)